AOL Web Search

  1. About 66,400 search results
  1. Web results:
  2. Acorda Therapeutics Inc - Acorda to Acquire Biotie Therapies

    Acorda markets three FDA-approved therapies, including AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg. About Biotie Therapies. Biotie Therapies is a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders.

  3. Acorda has acquired Biotie Therapies. We invite you to explore to learn more about our company, including our continued development of BIotie clinical ...

  4. Biotie EFPIA Disclosures | Acorda Therapeutics

    Biotie Therapies Oy is a member company of Pharma Industry Finland (PIF) and follows the PIF Code of Ethics, which implements the Disclosure Code set forth by the ...

  5. Acorda bags PhIII Parkinson's drug in $363M Biotie buyout ...

    Acorda Therapeutics ($ACOR) has swooped in to buy Finland's Biotie ($BITI) for $363 million in cash, snagging a Phase III Parkinson's drug that is being lined up to follow its leading experimental drugs into the neurology market.

  6. Acorda to Acquire Biotie Therapies | Business Wire

    Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it entered into an agreement to acquire Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; N

  7. Acorda Acquires Biotie for $363 Million - WSJ

    Biotechnology company Acorda Therapeutics Inc. on Monday said it acquired biopharmaceutical Biotie Therapies Corp. for $363 million. The deal, in which Acorda said it ...

  8. Acorda to Acquire Biotie Therapies – MTS Partners

    Biotie is headquartered in Turku, Finland, with clinical operations based in South San Francisco, CA. Following the close of the acquisition, Acorda plans to maintain the South San Francisco location and retain Biotie staff at that site. Acorda is considering the long-term future of the Turku facility.


  10. Acorda Therapeutics To Acquire Biotie Therapies To Boost ...

    Acorda Therapeutics Inc ... Acorda Therapeutics To Acquire Biotie Therapies To Boost Its Parkinson's Disease Therapeutic Development. Jayson Derrick.

  11. Acorda Therapeutics Inc - Investors - Investor News

    Enter the code shown above. * Text size. Normal; Larger; Largest; Print; ABOUT ACORDA; Company Leadership; Management Team; Board of Directors